Enfuvirtide, the first fusion inhibitor to treat HIV infection

被引:0
|
作者
Poveda, E [1 ]
Briz, V [1 ]
Soriano, V [1 ]
机构
[1] Hosp Carlos III, Dept Infect Dis, Madrid, Spain
关键词
HIV; enfuvirtide; fusion inhibitors; resistance; viral fitness;
D O I
暂无
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Entry inhibitors are a new class of drugs for the treatment of HIV infection. Enfuvirtide is the first compound of this family to be approved for clinical use. It blocks HIV fusion to host cells. It is a synthetic peptide that mimics an HR2 fragment of gp41, blocking the formation of a six-helix bundle structure which is critical in the fusion process. Enfuvirtide is a good therapeutic option as rescue therapy in combination with other active antiretrovirals and works against different HIV-1 variants, including all group M subtypes and group O. However, it is not active against HIV-2. The main mechanism of resistance to enfuvirtide depends of the selection of changes in a 10-amino acid domain between residues 36 to 45 in the HR1 region of gp41. Single and double mutations in this region have been shown to result in high-level resistance to enfuvirtide. A negative impact of enfuvirtide-resistance mutations on viral fitness has been postulated, since resistance mutations tend to disappear soon after drug discontinuation and because immunologic benefits have been noticed despite virologic failure in patients undergoing entuvirtide treatment.
引用
收藏
页码:139 / 147
页数:9
相关论文
共 50 条
  • [31] Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America (vol 348, pg 2175, 2003)
    Lalezari, JP
    NEW ENGLAND JOURNAL OF MEDICINE, 2003, 349 (11): : 1100 - 1100
  • [32] Atazanavir: A new protease inhibitor to treat HIV infection
    Musial, BL
    Chojnacki, JK
    Coleman, CI
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2004, 61 (13) : 1365 - 1374
  • [33] Could enfuvirtide ameliorate the pathogenesis of HIV infection?
    Poveda, E
    AIDS REVIEWS, 2004, 6 (02) : 117 - 118
  • [34] A prospective clinical and pathological examination of injection site reactions with the HIV-1 fusion inhibitor enfuvirtide
    Myers, Sarah A.
    Selim, Angelica A.
    McDaniel, Margaret A.
    Hall, Russell
    Zhang, Ying
    Bartlett, John A.
    True, Andrea L.
    ANTIVIRAL THERAPY, 2006, 11 (07) : 935 - 939
  • [35] Enfuvirtide: a new class of antiretroviral therapy for HIV infection
    Leao, JC
    Frezzini, C
    Porter, S
    ORAL DISEASES, 2004, 10 (06) : 327 - 329
  • [36] Enfuvirtide - A review of its use in the management of HIV infection
    Oldfield, V
    Keating, GM
    Plosker, G
    DRUGS, 2005, 65 (08) : 1139 - 1160
  • [37] Enfuvirtide, an HIV-1 fusion inhibitor peptide, can act as a potent SARS-CoV-2 fusion inhibitor: an in silico drug repurposing study
    Ahmadi, Khadijeh
    Farasat, Alireza
    Rostamian, Mosayeb
    Johari, Behrooz
    Madanchi, Hamid
    JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS, 2022, 40 (12): : 5566 - 5576
  • [38] Enfuvirtide for prophylaxis against HIV infection - The authors reply
    Ferranti, S
    Menichetti, F
    NEW ENGLAND JOURNAL OF MEDICINE, 2003, 349 (22): : 2170 - 2170
  • [39] HIV-1 Fusion Inhibitor Peptides Enfuvirtide and T-1249 Interact with Erythrocyte and Lymphocyte Membranes
    Matos, Pedro M.
    Castanho, Miguel A. R. B.
    Santos, Nuno C.
    PLOS ONE, 2010, 5 (03):
  • [40] Clinical management of treatment-experienced, HIV-infected patients with the fusion inhibitor enfuvirtide: consensus recommendations
    Clotet, B
    Raffi, F
    Cooper, D
    Delfraissy, JF
    Lazzarin, A
    Moyle, G
    Rockstroh, J
    Soriano, V
    Schapiro, J
    AIDS, 2004, 18 (08) : 1137 - 1146